The report forecasted that the Alzheimer's disease market in these countries to grow from $2.4 billion in 2023 to $19.3 ...

A predictive tool for determining the age at which individuals may develop mild cognitive impairment (MCI) or Alzheimer's ...

The Phase Ia trial is designed to assess the company’s drug designed to target chemicals thought to be a cause of Alzheimer’s disease.

Several recent studies have suggested HRT is a risk factor in various conditions, notably Alzheimer's - now UK boffins have ...

The Alzheimer’s disease market is expected to grow at a CAGR of 23.4% from $2.4bn in 2023 to $19.3bn by 2033 across the 8MM ...

Posdinemab works by targeting and neutralizing Alzheimer disease-specific phosphorylated tau, preventing its spread to other neurons.

Building on decades of the Company's Alzheimer's research, two differentiated investigational therapies aim to slow pathological tau in distinct populations Fast Track ...

NDAQ:TLSA) Tiziana Life Sciences Announces Review Article Published in Nature Highlighting Foralumab's Potential in the Treatment of Neurological Disease ...

For decades, scientists have been trying to develop therapeutics for people living with Alzheimer’s disease, a progressive ...

INmune Bio's XPro targets neuroinflammation, showing promising biomarker results in Alzheimer's, with a potential to ...

or general confusion stemming from memory loss. It can be distressing for everyone. This behaviour can happen at any stage of the disease. Wanting to do home, or fixating on the idea of going home, ...